Fig. 3.

a–d CD4⁺ICOS⁺, CD4⁺PD1⁺, CD8⁺ HLA-DR⁺ and CD8⁺ICOS⁺ cells in patients with clinical response or absence of response over time (*p < 0.05) (PR partial response, PD progressive disease). e Combination of CD8 ICOS and CD4 PD-1 suggested that the combination can be relevant to response of the patients to therapy (N non-responders; R responders)